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INTRODUCTION 
Epilepsy is a common neurological disorder with an estimated prevalence in 
Europe of 4.3-7.8 per 1000 [1]. Despite advances in antiepileptic drug (AED) 
therapy about one-third of patients with epilepsy are resistant to drug treatment 
[2]. Most patients with refractory epilepsy are resistant to several, if not all, 
AEDs, even though these drugs act by diverse mechanisms [3].  
Temporal lobe epilepsy (TLE) is the most common focal epilepsy. The most 
common cause of TLE in surgical series is hippocampal sclerosis (HS), which 
can be reliably detected in vivo by magnetic resonance imaging (MRI) [4]. 
Structural damage in TLE associated with HS is a condition that characterises 
mesial temporal lobe epilepsy (mTLE). Such damage and dysfunction frequently 
extends beyond the hippocampus into the parahippocampal and entorhinal 
cortex [5]. In this review we will first describe one putative mechanism of 
pharmacoesistance in epilepsy, the transporter hypothesis, and then discuss 
preclinical and clinical studies investigating ABC transporters and 
pharmacoresistance in epilepsy and emphasize molecular imaging techniques 
as a help towards analysis of the mechanisms of pharmacoresistance in 
epilepsy. 
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PHARMACORESISTANT EPILEPSY 
Definition of pharmacoresistant epilepsy 
The concept of pharmacoresistant epilepsy seems to be self-explanatory, but for 
some years a universally agreed definition remained elusive. In 2010 the 
International League against Epilepsy suggested that  pharmacoresistant 
epilepsy  be defined as failure of adequate response to two tolerated and 
appropriately prescribed  AED schedules (whether as monotherapies or in 
combination) to achieve sustained seizure freedom [6]. 
There are several hypotheses that explain the mechanisms associated with 
pharmacoresistance in epilepsy. Current theories on the causes of pharmaco- 
resistance in epilepsy include the transporter hypothesis, the target hypothesis, 
the network hypothesis, the gene variant/methylation hypothesis and the intrin-
sic severity hypothesis. However, none of these hypotheses is currently a stand-
alone theory that is able to convincingly explain how drug resistance arises in 
human epilepsy [7]. 
The transporter hypothesis 
The drug transporter hypothesis proposes that pharmacoresistance is related to 
increased expression of multidrug efflux transporter proteins such as P-
glycoprotein (Pgp). These proteins are thought to prevent AED entry by actively 
extruding AEDs from their target site [8]. Multidrug efflux transporters are highly 
expressed in capillary endothelial cells and astrocytic foot processes that form 
the Blood-Brain Barrier (BBB). They limit intracellular concentration of substrates 
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by pumping them out of the cell through an active energy-dependent 
mechanism. Pgp (encoded by the adenosine triphosphate (ATP)-binding 
cassette subfamily B member 1 gene (ABCB1) was discovered more than thirty 
years ago [9] and it is the multidrug efflux transporter protein we know most 
about in terms of its structure and mechanism. Epilepsy was the first CNS 
disorder for which pharmacoresistance was associated with enhanced 
expression of Pgp in the brain [10]. Pathologically elevated expression of Pgp 
has been found in resected brain tissue of patients with pharmacoresistant 
mTLE undergoing surgery [8] as well as in limbic brain regions of mouse and rat 
models of mTLE [11]. It is currently not clear whether the endothelial and 
parenchymal overexpression of Pgp is a consequence of epilepsy, of 
uncontrolled seizures, of chronic treatment with AEDs, or is constitutive, i.e. 
present before the onset of epilepsy [11].  
Blood-brain barrier  
The blood-brain barrier (BBB) is a physical and metabolic barrier between the 
brain and the systemic circulation [12]. The BBB is composed of a monolayer of 
brain capillary endothelial cells. Unlike capillaries in other parts of the body, the 
cerebral capillaries are joined by tight junctions, which restrict solute flux 
between the blood and the brain. The brain capillary endothelial cells are 
surrounded by extracellular matrix, pericytes, and astrocyte foot processes [13]. 
Circulating molecules gain access to the brain via one of two processes: 1) lipid-
mediated transport of small nonpolar molecules through the BBB by free 
(passive) diffusion, or 2) catalyzed transport [12, 13].  
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The endothelial cells of the BBB contain numerous membrane transporters 
involved in the influx and efflux of essential substrates [14]. ABC efflux 
transporters, such as Pgp, at the BBB limit the brain uptake of a variety of 
therapeutic agents, including compounds that are relatively lipophilic and would 
be predicted to permeate the endothelial lining of the brain microvasculature 
[15]. Pgp is located at the luminal (apical = blood-facing side) membrane of 
endothelial cells [16, 17]. Thus, Pgp substrates entering the endothelial cells 
from blood are immediately pumped back into blood. As a consequence, the net 
penetration of substrate compounds from the blood into the brain tissue can be 
dramatically decreased. In the absence of Pgp in the BBB, the brain penetration 
of Pgp substrate drugs can increase up to ten - to 100-fold, with sometimes 
dramatic consequences for the toxicity of compounds [16]. Furthermore, 
blockade of BBB Pgp by cerebral application of Pgp inhibitors significantly 
increases the brain concentration of various drugs, again being in line with Pgp 
functioning as an efflux transporter in the BBB [18]. 
Clear expression of Pgp in astrocytes is especially seen in certain pathological 
states such as epilepsy [19].   
In contrast to Pgp, data on the other ABC transporters in the BBB are much 
more limited [16]. At least six multidrug resistant proteins (MRP) (MRP1-6) are 
expressed at the BBB of different species. However, the exact subcellular 
localization (apical vs basolateral) of most of these MRPs in brain capillary 
endothelial cells remains to be determined [11].  
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Blood-cerebrospinal-fluid barrier  
Several drug efflux transporters are present in epithelial cells of the blood- 
cerebrospinal-fluid (CSF) barrier. However, in contrast to the BBB, the exact 
functional role of efflux transporters in these other brain barrier is less well 
understood [18]. The blood-CSF barrier is located at the choroid plexus (CP) 
and the outer arachnoid membrane. The blood-CSF barrier plays a vital role in 
the selectivity and permeability of the CP membrane to various nutrients and 
xenobiotics [14]. The CP, which is the main source for CSF production, is a leaf-
like highly vascular organ that projects into the ventricles of the brain and 
functions as a highly regulated solute- and drug-permeability barrier. The apical 
surface area has a same size range as the luminal surface area of the 
endothelial cells of the BBB, thereby providing a similarly large surface for solute 
exchange [18]. The CP is comprised of fenestrated, highly permeable capillaries 
at the blood side that are surrounded by stroma and a monolayer of epithelial 
cells that face the CSF and are joined together by tight junctions [14]. Once a 
solute or drug has crossed the capillary wall, it must penetrate the epithelial cells 
before entering the CSF [18].  
The molecular identity and localization of the proteins responsible for the influx 
and efflux of drugs and metabolites at the CP are currently explored. Transport 
of drugs and metabolites involves mainly the solute carrier and ABC transporters 
[14, 20, 21]. Rao et al. [22] first described the expression of Pgp and MRP1 in 
the epithelia of the CP and their contribution in a bipolar permeation barrier for 
selected drugs crossing the blood-CSF barrier [18]. It was concluded that Pgp 
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localizes sub-apically at the CP with transport into the direction of CSF, whereas 
MRP1 localizes basolaterally, conferring transport to the blood side of epithelial 
cells [22]. Thus, in the choroidal epithelium, Pgp and MRP1 seem to have 
opposing drug-transport functions. The basolateral localization of MRP1 at the 
CP epithelium was subsequently confirmed by other groups [23]. However, in 
general, the role of these and other drug transporters in blood-CSF barrier 
function is only incompletely understood and more studies need to be done [18]. 
ABC transporters: function and role in pharmacoresistance 
Active drug efflux transporters of the ATP binding cassette (ABC)-containing 
family of proteins have a major impact on the pharmacological behaviour of 
most of the drugs in use today. The penetration of drugs into a range of 
important pharmacological sanctuaries, such as brain, testis, and fetus, and the 
penetration into specific cell- and tissue compartments can be extensively 
limited by ABC transporters [16, 24]. ABC transporters are expressed in many 
tissues including the intestine, liver, kidney, brain and they maintain chemical 
homeostasis by mediating the transport of molecules across a membrane 
irrespective of concentration gradient. These transporters are encoded by 49 
genes in the human genome and have been grouped into seven subfamilies 
(designated ABCA-ABCG) based on sequence homology [25-27]. ABC 
transporters in their functional form comprise a minimum of four core domains 
that form the permeation pathway for transport of substrates, and two nucleotide 
binding domains that hydrolyze adenosine triphosphate (ATP) to power this 
process. Three ABC proteins appear to account for most observed multidrug 
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resistance (MDR) in humans and rodents [28]; P-glycoprotein 
(Pgp/MDR1/ABCB1), MDR-associated protein (MRP)1 (ABCC1) and breast 
cancer resistance protein ABCG2 (variously known as BCRP, ABCP for its high 
expression in placenta or MXR for mitoxantrone resistance) [29]. We will focus 
on these three most important multidrug transporters; however the family of 
mammalian ABC transporters is far more extensive and functionally highly 
diverse [30]. 
P-glycoprotein 
Pgp was discovered more than 30 years ago [9] and it is the ABC protein we 
know most about in terms of its structure and mechanism. Pgp is generally 
expressed at higher levels in epithelial cell surfaces throughout the body. It is 
found exclusively at the apical surface of cells in the kidney proximal tubule, 
canalicular membrane of hepatocytes, pancreas, the villous membrane of the 
small and large intestine and the adrenal gland [31, 32]. Pgp is also located in 
blood-tissue barriers, including the placenta and endometrium, blood-inner ear 
barrier, blood-mammary tissue barrier, blood-testis barrier, blood-nerve barrier, 
blood- brain barrier (where it is exclusively oriented to transport substrates 
toward blood) and epithelial cells of the blood-CSF barrier [22, 33]. Pgp either 
restricts drug-entry to the body via the gastrointestinal tract and excretes 
metabolites into the urine or gastrointestinal tract or prevents their access from 
the blood to the fetus and sensitive organs such as the brain and testis [33].  
Pgp is a phosphorylated glycoprotein with an apparent molecular weight of 
170kDA [18]. There are two types of human Pgp: type I, encoded by the MDR 1 
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gene (ABCB1), which confers the drug resistance phenotype and promotes drug 
efflux at the blood-brain barrier, and type II, encoded by (ABCB2), present in the 
canalicular membrane of hepatocytes and functioning as phosphatidylcholine 
translocase [34]. The MDR1 gene in humans is located on chromosome seven 
and has 28 exons [35]. Structurally the transporter consists of two interwoven 
transmembrane regions, each containing six transmembrane helices and an 
ATP-binding site located intracellularly. The transmembrane helices of Pgp allow 
it to bind and induce efflux of a broad range of substrates with varying affinities 
[36]. Although substrates for Pgp tend to be hydrophobic or weak base 
molecules with a planar ring system, Pgp is considered polyspecific because it 
can recognize a wide range of substrates including antiarrhythmics, 
antihistamines, cholesterol-lowering statins and human immunodeficiency virus 
protease inhibitors [26].  
Multidrug resistance protein 
The multidrug resistance protein (MRP) 1 was discovered in 1992 by Cole [37] 
and co-workers and the MRP family of proteins comprised nine characterized 
members (MRP1-9) also named ABCC1-6 and 10-12, respectively. Among MRP 
proteins, MRP1 is the most studied and like Pgp, MRP1 is an ATP-dependent 
transporter. It is expressed at low levels throughout many normal tissues and 
cell types in the body, but it is more highly expressed in the adrenal gland, 
bladder, CP, colon, erythrocytes, kidney, lung, placenta, spleen, stomach, testis, 
helper T-cells and muscle (both skeletal and cardiac) [33]. In contrast to Pgp 
and MRP2, it is localized on the basolateral membranes in polarized cells [38]. 
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The basolateral localization of MRP1 serves to protect sensitive tissues. For 
example, basolateral expression of MRP1 in the CP allows the protein to 
transport drugs from the cerebrospinal fluid to the blood to protect sensitive 
nervous tissues [22]. MRP1 is a 190-kDa protein containing 1531 amino acids 
and its cognate gene is located on chromosome 16p13.11 [39]. MRP1 functions 
mainly as a co-transporter of amphipathic organic anions. It can transport 
hydrophobic drugs or other compounds that are conjugated or complexed to the 
anionic tripeptide glutathione, glucuronic acid, or to sulfate [16].  
Breast cancer resistance protein  
In the early 1990s several groups began reporting non-Pgp, non-MRP1-
mediated pharmacoresistance in a variety of drug selected cell lines [40, 41]. 
The gene responsible for the novel phenotype was first cloned by Doyle and 
colleagues from a breast cancer cell line and was therefore called BCRP for 
breast cancer resistance protein [42]. Like Pgp, the breast cancer resistance 
protein (BCRP) is also localized to the apical face of polarized membranes. It is 
found in epithelial cells of the intestine, human placenta syncytiotrophoblasts, 
liver bile canaliculi, prostate, brain, lobules and lactiferous ducts of the 
mammary gland, and renal tubules, as well as the endothelium of veins and 
capillaries, including those at the blood-brain barrier and the placenta [33, 42]. 
Based on messenger ribonucleic acid (mRNA) analysis ABCG2 was more 
strongly expressed at the BBB than Pgp or MRP1 [43]. 
The tissue distribution of BCRP shows extensive overlap with that of Pgp, 
suggesting that it might have a similar role as Pgp in the pharmacological 
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handling of substrate drugs. It appears to transport both positively and 
negatively charged drugs, including sulfate conjugates and the list of its 
substrates is rapidly expanding, highlighting the importance of this protein [28]. 
MECHANISMS OF PGP OVEREXPRESSION IN 
PHARMACORESISTANT EPILEPSY 
An important question is whether the overexpression of efflux transporters in 
epileptic brain tissue is constitutive or acquired/induced, or both mechanisms 
may be at play. A constitutive overexpression could occur as a result of a 
genetic predisposition, or it could be intrinsic to the development of the specific 
pathology. It is also conceivable that overexpression is acquired such as 
induction by recurrent seizures or even the AEDs intended to prevent them [3]. 
We will discuss the evidence for the possible various mechanisms in the 
following paragraphs. 
Seizures induce Pgp overexpression 
In rats and mice, experimentally induced seizures have been shown to increase 
the expression of Pgp in brain capillary endothelial cells (BCECs), astrocytes 
and neurons [18]. Zhang et al. [44] reported increased Pgp expression in the 
hippocampus following intracerebroventricular injection of kainate in rats, 
causing neuronal injury. This increase in Pgp expression was observed in 
reactive astrocytes as early as one day after injection, peaked at two weeks but 
was still visible at ten weeks. Seeger et al. [45] studied Pgp expression at 24 
hours and ten days after status epilepticus (SE) (to differentiate between seizure 
related changes and changes developing during epileptogenesis). Pgp 
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increased significantly 24 hours after kainate-induced SE in BCECs at the 
dentate gyrus, amygdala, piriform and parietal gyrus. Additionally in the brain 
parenchyma of rats 24 hours after SE, a significant increase in Pgp expression 
was observed in the piriform and parietal cortex, dentate gyrus and 
hippocampus. However, the alterations in Pgp expression were only transient 
and disappeared ten days after the SE, except for the dentate hilus and the CA1 
sector of the hippocampus, in which a significant increase in parenchymal Pgp 
was observed ten days after the status. Following systemic injection of kainate 
in mice, expression of mdr-1, the gene encoding Pgp, was found to be increased 
in the hippocampus for three-24 hours after the seizures but returned to control 
level by 72 hours [46]. Recently Pekcec et al. [47] studied Pgp expression in 
brain tissue sampled from epileptic dogs following spontaneous status 
epilepticus or seizure clusters to avoid a putative bias of status epilepticus 
induction. They demonstrated a significant upregulation of Pgp in the 
hippocampal hilus (82% above control), the dentate gyrus granule cell layer 
(132% above control) and parietal cortex of canines (123% above control) one-
seven days following a seizure. In further support of the temporal increase of 
Pgp after seizures is the study by Bankstahl and co-workers [48] in two rat SE 
models. Immunohistochemical staining of Pgp did not indicate any increase of 
Pgp expression in brain capillary endothelial cells during SE, whereas significant 
overexpression was determined in both models 48 hours after SE. Seven days 
after SE, Pgp expression had returned to control levels [48]. Löscher and 
Potschka [11] suggested that the excitatory neurotransmitter glutamate, which is 
excessively released by seizures, is involved in the seizure-induced over-
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expression of Pgp in the brain. This suggestion was based on a report by Zhu 
and Liu [49], showing that glutamate up regulates the expression and functional 
activity of Pgp in rat BCECs in vitro. They suggested that glutamate upregulates 
Pgp expression in BCECs by an N-methyl-D-aspartate (NMDA) receptor-
mediated mechanism, which could play a role during ischemic and anoxic injury. 
Bankstahl et al. [50] recently examined this hypothesis and evaluated whether 
glutamate is involved in seizure-induced upregulation of Pgp in brain capillaries 
after systemic-administration of pilocarpine, a model of mTLE. Their data shows 
that the administration of the glutamate receptor antagonist MK-801 after 
convulsive SE prevents the upregulation of Pgp in brain microvessels in the 
hippocampus, indicating that SE-induced glutamate release is involved in the 
regulation of Pgp expression after seizures. Additionally MK-801 reduces the 
neuronal damage after prolonged seizures which may offer a therapeutic option. 
The activation of the NMDA receptor by glutamate is known to generate reactive 
oxygen species (ROS) and Zhu and Liu [49] suggested that ROS may mediate 
the effect of glutamate on Pgp expression. Generation of free radicals such as 
ROS has been suggested to play a key role in neuronal damage developing 
after SE. It is generally believed that excitotoxic cell death is due to excessive 
activation of NMDA receptors by glutamate, leading to excessive activation of 
calcium ion influx through the receptor’s associated ion channels and 
subsequent free radical production, including ROS. Based on this hypothesis, 
ROS is likely to be the link between seizures induced glutamate release and 
over-expression of Pgp. The data from these animal studies indicate that Pgp 
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overexpression is a result of sustained seizure activity but not of the processes 
underlying development of epilepsy. 
Brain inflammation and epilepsy 
It is widely accepted that neuronal dysfunctions are the cause of seizures and 
targeting of neuronal ion channels, GABA, and glutamate receptors has been, 
for decades, the mainstream pharmacological approach to eradicate seizures. 
Although the ultimate effectors of seizures are neurons, recent advances in 
experimental neurology have revealed that inflammation can precipitate seizures 
or sustain seizure activity [51]. Two distinct inflammatory processes have been 
linked to seizures. Neuroinflammation is present in epileptic brain where it 
exacerbates seizures or increases their frequency [52]. By contrast, systemic 
inflammation can cause epileptiform neuronal discharge via loss of ionic (e.g., 
potassium [53]) and neurotransmitter (e.g., glutamate [51, 54]) homeostasis. 
Although neuroinflammation directly affects neurovascular and glial function, the 
effects of systemic inflammation are mediated or facilitated by loss of BBB 
function [55]. BBB disruption can be triggered by a direct insult to the 
endothelium [56] or by systemic factors, including activation of circulating 
leukocytes and release of molecular mediators that increase vascular 
permeability [51, 57]. Pro-inflammatory and anti-inflammatory cytokines, 
chemokines, and prostaglandins are responsible for the production of an early 
immune response. Numerous studies have confirmed enhanced inflammatory 
signalling in chronic rodent models and in tissue from patients with TLE [58, 59]. 
Genetic and pharmacological modulation of the synthesis and secretion of 
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inflammatory mediators and of their receptors can influence seizure thresholds, 
severity and duration in mouse and rat TLE models [59]. Anti-inflammatory 
drugs, such as steroids and intravenous immunoglobulins, are useful in selected 
pharmacoresistant epileptic syndromes, whereas fever, immunization, and trivial 
infection can precipitate seizures, providing a solid link between inflammation 
and seizures [60]. In addition, inflammatory mediators seem to contribute to 
disease-associated alterations, which can exert an effect on antiepileptic drug 
responses. For instance, cytokines, such as interleukin (IL) - IL-1 β,IL-2, IL-6 
and tumor necrosis factor- α (TNF- α), can modulate the expression, sub-unit 
composition and functional state of antiepileptic drug targets [59, 61, 62].  
Pgp overexpression and brain inflammation 
Further downstream events in the signalling cascade have been identified and 
Bauer et al [63] have shown that cyclooxygenase-2 (COX-2) is a central factor of 
a cascade that drives the transcriptional activation of the Pgp-encoding gene in 
the epileptic brain. COX is an enzyme that is responsible for the formation of 
prostanoids, including prostaglandins, prostacyclin and thromboxane. These 
lipid mediators play important roles in inflammation and pain and in normal 
physiological functions.  Pharmacological inhibition of COX can provide relief 
from the symptoms of inflammation and pain. It has been proven that COX-2 
mediates Pgp regulation in response to excess glutamate concentrations such 
as those occurring during epileptic seizures [64]. It is known that glutaminergic 
signaling increases COX-2 expression and that at least in rat mesangial cells 
COX-2 activation leads to increased Pgp [65]. Furthermore, both the 
15 
 
nonselective COX inhibitor indomethacin as well as the selective COX-2 inhibitor 
celecoxib counteracted Pgp increase by glutamate exposure of isolated rat brain 
capillaries. Van Vliet et al. tested the efficacy of COX-2 inhibitors in a chronic 
rodent model, overexpressing Pgp [66, 67]. A sub-chronic 2-week treatment with 
the highly selective COX-2 inhibitor SC-58236 in the chronic epileptic state kept 
Pgp expression at control levels [68]. These data substantiate that COX-2 
inhibition can block repeated induction of Pgp by ongoing seizure activity, 
thereby allowing Pgp to return to control levels. Furthermore, enhanced Pgp 
expression in chronic epileptic rats was associated with a significant reduction in 
the brain penetration of the antiepileptic drug phenytoin. Importantly, the brain 
delivery of phenytoin was significantly enhanced by subchronic COX-2 inhibition 
in rats with recurrent seizure activity [68]. These data provided evidence that 
COX-2 inhibition may help to increase concentrations of AEDs at the target sites 
and that COX-2 inhibition could be a novel therapeutic concept to overcome 
pharmacoresistance in epilepsies [69].  
Genetic polymorphism and Pgp expression 
Several studies have tested for an association between Pgp expression in 
patients with epilepsy and polymorphism in drug transporter genes [70]. One of 
these, a single nucleotide polymorphism in exon 26 (C3435T) of the MDR1 gene 
is associated with altered expression, functionality and substrate specificity of 
the MDR1 product Pgp. Based on an initial report by Siddiqui [71], a series of 
studies supported the hypothesis that the C3435T polymorphism is associated 
with resistance to multiple AEDs [72]. Several recent genetic association studies 
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have also indicated an association of the 3435CC genotype with increased Pgp 
expression and drug resistant epilepsy [72]. In contrast however are other 
studies which did not find a link between ABCB1 and response to AEDs [72]. 
Two metaanalyses including 11 studies up to September 2007 involving 3371 
patients and including 22 studies up to February 2010 involving 6755 patients 
respectively provided no support for an association between 
pharmacoresistance and ABCB1 [73, 74].  The inconsistency between the 
studies might be caused by different inclusion criteria (definition of 
pharmacoresistance, co-morbidities, co-medication and population structure). A 
recent study pointed out the importance of stratification by patient age and 
aetiology of epilepsy [75]. Another issue is the selection of AEDs included in the 
studies as the inclusion of drugs which have not been confirmed as Pgp 
substrates will bias the data [69]. Another factor complicating genetic 
association studies is related to data indicating that the C3435T polymorphism 
might have contrasting consequences on Pgp expression in different ethnic 
subgroups. This is in line with the observation that an association in the opposite 
direction has been described in studies in Asian patients as compared to studies 
reporting an association in a Caucasian patient population [76]. 
Are antiepileptic drugs Pgp substrates? 
A central question of the transporter hypothesis is whether AEDs are substrates 
for Pgp. Only then, could overexpression of Pgp crucially contribute to 
pharmacoresistance in epilepsy. So far evidence has been reported that 
phenytoin, phenobarbital, lamotrigine, levetiracetam, topiramate, and 
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carbamazepine and oxcarbazepine metabolite are substrates of human Pgp [77-
79]. On the other hand data argue against a transport of valproic acid and 
carbamazepine [79, 80]. In addition, transport of AEDs has been evaluated in a 
human colon carcinoma cell line. In these in vitro assays no evidence was 
obtained that carbamazepine, vigabatrine, gabapentin, phenobarbital, or 
lamotrigine are substrate of Pgp [81, 82]. Moreover, Rivers et al. reported that 
carbamazepine, valproic acid, phenytoin, lamotrigin, and primidone are not likely 
to be substrates of Pgp based on their investigations in breast and cancer cell 
lines [83]. Although in vitro and in vivo transport assays have indicated that 
several antiepileptic drugs are substrates of Pgp, and that some AEDs are 
transported by ABC transporters, the data however is controversial. Although 
apparently a simple question, obvious difficulties exist in research evaluating the 
transporter substrate characteristics of AEDs. AEDs can pass the BBB 
efficaciously when efflux transporters such as Pgp are expressed at basal level. 
However, their brain penetration is limited once a relevant over expression 
occurs. Highly lipophilic compounds can rapidly diffuse through membranes of 
endothelial cells and might be less sensitive to an impact of active transports. 
Furthermore differences in the affinity to the transporter molecule might exist. 
Respective differences need to be taken into consideration when choosing an in 
vitro assay to explore the substrate specificities of AEDs. It has also been 
recently demonstrated that the transport of AEDs depends on concentration and 
it is therefore of particular relevance to test potential Pgp substrates at clinically 
relevant concentrations [84]. Additionally, recent data also suggests that the 
substrate recognition or transport efficacy by Pgp differs between human and 
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mouse for certain AEDs [85, 86]. Such differences might explain in part the 
controversial data which have been reported for AED transport by Pgp from 
different species [3]. 
Antiepileptic drugs induce Pgp overexpression 
Some studies have indicated that antiepileptic drugs might contribute to the 
induction of Pgp overexpression [69]. Lü et  al.  [87] showed in astrocyte cell 
cultures from postnatal Wistar rats that the antiepileptic drugs phenytoin, 
phenobarbital, carbamazepine, and valproic acid induced the overexpression of 
Pgp in astrocytes in a dose- and time-dependent manner. Significantly higher 
levels of Pgp staining were detected at therapeutic concentrations of certain 
antiepileptic drugs (20 microg/ml phenobarbital, 40 microg/ml phenobarbital, and 
20 microg/ml phenytoin) on day 30. Upregulation of Pgp was detected when 
using higher concentrations of phenytoin, phenobarbital, and valproic acid on 
day 20 and when using higher concentrations of any of the four antiepileptic 
drugs on day 30.  Similarily, Lombardo et al. [88] reported that carbamazepine, 
phenobarbital, and phenytoin induce Pgp and other transporters in rat brain 
endothelial cell lines via and interaction with the pregnane x receptor and the 
constitutive androstane receptor. In contrast Ambroziak el al. [89] did not 
observe effects of these AEDs on expression and functionality of Pgp. Therefore 
definite conclusions regarding the impact of AEDs require further future efforts 
[69]. 
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PRECLINICAL STUDIES OF PGP IN MTLE 
Preclinical epilepsy models 
Knockout mice and natural mutants 
Investigations in genetically deficient animals, which lack a functional form of 
one or more drug efflux transporter, have contributed to a significant extent to 
the current knowledge about the physiological and pharmacological function of 
these transporters. Genetically deficient mice have been generated by knockout 
technologies with the purpose of studying the role of specific transporters. 
Furthermore, subpopulations of animals with spontaneous mutations in 
multidrug transporter genes have been identified for different species. The in 
vivo impact of Pgp in the BBB has been intensely studied in knockout mice 
lacking the Pgp isoform mdr1a (mdr1a (-/-) mice) or mdr1a and mdr1b Pgp 
(md1a/1b (-/-) mice). Mdr1a knockout mice lack the mdr1a isoform of Pgp all 
over the body and in the brain capillary endothelial cells. The animals are viable 
and fertile but are more susceptible to developing a severe, spontaneous 
intestinal inflammation [11]. 
Animal models of epilepsy 
Animal models of epilepsy are a valuable tool to study models of seizure onset, 
neurologic changes during seizures, and new pharmacologic tools for seizure 
propagation or pharmacoresistance. For epilepsy research various animal 
models are available, each with their specific characteristics. Globally, these 
models are categorized into models of seizures and those of epilepsy [90]. 
Examples of seizures, or acute, models are the cortical stimulation model and 
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the maximal electroshock model. The amygdala kindling model is also an acute 
model, as most animals do not develop spontaneous epilepsy. The models of 
epilepsy, chronic models, can be subdivided into models of genetic epilepsy and 
models of acquired (symptomatic) epilepsy [91]. The first category includes both 
animals with spontaneous mutations and animals with induced mutations, 
resulting in epileptic symptoms and behavior. In animals of the acquired or 
symptomatic epilepsy models, status epilepticus (SE) is induced by electrical 
stimulation (amygdala, perforant path, and hippocampus) or through the 
administration of chemical convulsants (pilocarpine or kainic acid) in previously 
non-epileptic rats, which results in the development of spontaneous seizures 
after a latent period of days to weeks [92].  
Kindling model 
Since its introduction by Goddard in 1967 [93], the kindling model has been 
used extensively as an animal model of epilepsy. Kindling can be induced by the 
repeated administration of a mild electric stimulus to the rat brain via an 
implanted electrode into a limbic structure such as the amygdala, hippocampus, 
entorhinal cortex or other brain areas. Over a period of several stimulation 
session the rat reliably displays stage five seizures, according to the Racine 
scales [94]. The pathophysiology of kindling is very similar to that of human 
mTLE. For example, kindling leads to structural and functional changes 
characterized by neuronal cell loss, gliosis, neurogenesis and mossy fiber 
spouting [95, 96]. 
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Pilocarpine model 
The pilocarpine and the kainic acid model are probably the most commonly 
studied chemical-inductive models for mTLE. Pilocarpine, a potent muscarinic 
cholinergic agonist, is administered as a single high dose (300-380mg/kg) to rats 
or mice. It acutely induces sequential behavioral and electrographic changes, 
indicative of sustained epileptic activity, resulting in widespread damage to the 
forebrain. After 15-25 minutes this results in motorlimbic seizures and leads to 
SE within 50-60 minutes after pilocarpine administration that last for up to 12 
hours. After a silent period of a few days animals start exhibiting spontaneous 
recurrent seizures. Morphological analysis of the brain after pilocarpine-indcued 
SE demonstrates cell loss in the hippocampal subfields CA1 and CA3 and in the 
hilus of the dentate gyurs, in the septum, olfactory tubercle, amygdala, piriform 
cortex, neocortex and thalamic nuclei [97, 98]. 
Kainic acid model 
The excitotoxic glutamate analogue kainate can be systemically or 
intracerebrally injected into an animal and rapidly produce acute seizures. In 
rodents, large doses of the drug induce severe acute seizures with subsequent 
SE, which is followed by a quiescent period of usually several weeks [99]. This 
latent period is followed by the development of spontaneous recurrent seizures. 
Injections of kainic acid were shown to lead to cell death in the hippocampus, 
amygdala, entorhinal cortex and medial thalamic nuclei [100]. 
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Preclinical studies of Pgp in epileptic rats 
In animals, models of temporal lobe epilepsy, such as the kindling and kainate 
models, have been used to study the molecular mechanisms of 
pharmacoresistance. In these models a large group of kindled or epileptic rats is 
treated with AEDs. Subsequently subgroups of animals that either respond 
(pharmacosensitive/seizure-free) or do not respond (pharmacoresistant) to 
AEDs are selected.  Pgp is overexpressed in endothelial cells and ectopically in 
astrocytes, after induction of sustained limbic seizures in rodents [101]. 
Upregulation of the mRNA of the MDR1 gene was detected in rat brain during 
both acute and spontaneous seizures caused by status epilepticus. More 
recently Volk and Löscher [101] used a rat model of temporal lobe epilepsy to 
examine whether Pgp expression differs in AED responders from non-
responders rats. In this model, spontaneous recurrent seizures develop after 
status epilepticus is induced by prolonged electrical stimulation of the 
basolateral amygdala. They showed that phenobarbital-resistant epileptic rats 
exhibit significantly higher endothelial expression of Pgp in limbic brain regions 
compared to drug-responsive rates providing further support for the hypothesis 
of Pgp overexpression in pharmacoresistant epilepsy. Furthermore in another 
study with amygdala epileptic kindled rats significant upregulation of Pgp was 
reported in brain capillary endothelial cells of limbic brain regions. In these rats, 
brain-to-plasma concentration ratios of phenytoin in the hippocampus were 
about 30% lower than those measured in control rats [102]. When kindled rats 
were divided into phenytoin responders and non responders, non responders 
exhibited a significantly higher expression of Pgp in capillary endothelial cells in 
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the epileptogenic focus [103].  Moreover, no differences in Pgp expression were 
observed in the adjacent piriform cortex indicating that the Pgp expression 
between non-responders and responders are restricted to the kindled focus 
[103]. Rizzi et al. [46] reported that mdr1 mRNA is overexpressed in mouse 
hippocampus after the induction of limbic seizures. Then phenytoin was 
systemically administered to the mice, its brain-to-plasma ratio was 30% less 
than in mice not subjected to seizures thus indicating reduced drug-
concentrations on brain. 
Moreover, targeting Pgp by modulators can enhance the efficacy of AEDs. The 
co-administration of the unselective inhibitor verapamil proved to potentiate the 
anticonvulsant efficacy of the AED oxcarbazepine [104]. The third generation 
selective modulator tariquidar (TQD) increased the efficacy of phenytoin in a 
chronic rat model where spontaneous recurrent seizures where induced by 
electrical stimulation [105]. However, putative species differences in the 
substrate spectrum of the transporters need to be taken into account when 
extrapolating from rodent data to the clinical situation. 
CLINICAL STUDIES OF PGP IN MTLE 
Evidence for increased expression of Pgp has mainly been derived from 
epileptic tissues removed during epilepsy surgery from patients with 
pharmacoresistant epilepsy [3]. Tishler et al. [10] were the first to measure 
MDR1 expression in 19 patients undergoing resective epilepsy surgery, 15 of 
whom had mTLE receiving temporal lobeectomy for a mixture of pathologies 
(mostly hippocampus sclerosis). MDR1 mRNA level was found to be ten times 
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higher in 11 of the 19 resected samples compared with controls. In addition Pgp 
was detected by immunohistochemical staining in astrocytes where it is not 
normally present, suggesting novel expression. Following Tishler and 
colleagues’ report multiple follow-up studies have confirmed this initial finding in 
patients with different types of epilepsy and different pathologies. Dombrowski et 
al. [106] applied cDNA array and found overexpression of MDR1, MRP2 and 
MRP5 in endothelial cells isolated from temporal lobe blood vessels of brain 
specimens from five pharmacoresistant patients undergoing temporal 
lobeectomy. Sisodiya et al. demonstrated both Pgp and MRP1 in astrocytic 
cells, but not in capillary endothelial cells, in the hippocampus in cases of 
hippocampal sclerosis [8]. More recently Aronica et al. [107] performed detailed 
immunostaining studies in brain sections from 16 patients with hippocampal 
sclerosis and found upregulation for Pgp and MRP2 in capillary endothelium 
consistent with an enhanced barrier function. MRP1 was detected in glial foot 
processes around blood vessels, possibly functioning as a “second line” defence 
mechanism. In addition, novel expression of Pgp, MRP1 and MRP2 was found 
in reactive astrocytes within the hippocampus in the CA1 and hilar regions. A 
recent post-mortem study showed Pgp overexpression in the sclerotic 
hippocampus of individuals with pharmacoresistant epilepsy, but not in post 
mortem seizure-free individuals or non-epileptogenic tissue with electrode-
related injuries [108].  
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CLINICAL STUDIES OF PGP IN OTHER EPILEPSY SYNDROMES 
Previous studies have shown that Pgp is ectopically expressed in surgically-
resected specimens from patients with pharmacoresistant epilepsy with a variety 
of structural abnormalities; including malformations of cortical development such 
as focal cortical dysplasia (FCD) [109, 110]. FCD is one of the most common 
causes of pharmacoresistant epilepsy. Evidence for Pg expression in FCD has 
mainly been performed in epileptogenic human brain tissue resected during 
epilepsy surgery. Sisodiya et al. [111] were the first to show an overexpression 
of Pgp in FCD. They studied four samples of surgically resected FCD and 
compared the findings with normal necropsy brain tissue. They showed an 
overexpression of Pgp in abnormal giant dysplastic neurons, glial cells, and in 
perivascular distribution in epileptogenic tissue. The authors extended their work 
by increasing the number of patients and included 14 patients with FCD in their 
study [8]. Their findings confirmed their previous work demonstrating an 
overexpression of Pgp also in astrocytes, dysmorphic neurons and balloon cells 
of patients with FCD. These findings have since been confirmed in several other 
studies [110, 112-114]. Ak et al. included a higher number of patients than the 
previously reported and studied the expression of Pgp in the epileptic tissues 
resected surgically in 28 patients with FCD and compared the results with 10 
normal necropsy brain tissues [110]. Normal brain showed no Pgp expression in 
neurons and astrocytes. In contrast to normal brain Pgp is intensely expressed 
in both neurons and reactive astrocytes in the vast majority of dysplastic tissues 
and endothelial cells of patients with FCD. These findings supported the 
‘transporter hypothesis’ that overexpression of multidrug efflux transporters in 
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epileptogenic brain regions may lower drug concentrations and thereby reducing 
their antiepileptic effects, which may explain the refractoriness to AEDs in FCD. 
However, although increased multidrug efflux transporter expression has been 
demonstrated in human tissue of patients with FCD that had been resected in 
surgery it may not be functionally relevant. Therefore non-invasive brain imaging 
of multidrug efflux transporter function in pharmacoresistant epilepsy patients is 
a strategy to evaluate whether the overexpression of multidrug efflux 
transporters at the BBB as postulated in the ‘transporter hypothesis’ has any 
functional consequences that underlie pharmacoresistance in epilepsy.  
NEUROIMAGING OF PGP WITH PET   
Non invasive brain imaging of multidrug efflux transporter function in 
pharmacoresistant and seizure-free epilepsy patients is a strategy to evaluate 
whether the overexpression of multidrug efflux transporters at the BBB as 
postulated in the transporter hypothesis has any functional consequences that 
underlie pharmacoresistance in epilepsy. Additionally, PET tracers for multidrug 
efflux transporters could be useful to identify epilepsy patients with increased 
multidrug efflux transporter activity who will benefit from treatment with multidrug 
efflux transporter modulation drugs and therefore hold great promises for 
individualized medicine [115]. 
Functional neuroimaging with PET and SPECT in Epilepsy 
Positron emission tomography (PET) and single photon emission computed 
tomography (SPECT) are imaging techniques that can study CNS function in 
vivo. Thereby a radionuclide is synthetically introduced into a molecule of 
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biological relevance and administered to a patient or animal. PET and SPECT 
cameras monitor the distribution of these radiotracers over time. In PET the 
radioisotope undergoes positron decay and emits a positron, which interacts 
with an electron in situ, producing a pair of annihilation photons moving in 
approximately opposite directions which can be detected outside the body by a 
PET camera [116]. In contrast with PET, the radiotracers used in SPECT emit a 
single photon (gamma ray) that is detected directly using collimators. By 
detecting photons "coincident" in time, PET provides more radiation event 
localization information and, thus, higher resolution images than SPECT. 
Therefore the great advantage of PET over SPECT is a higher sensitivity, better 
temporal and spatial resolution and ability to provide a quantitative measure of 
radioactivity in tissues. 
Almost all efforts to develop multidrug efflux transporters ligands have focused 
on Pgp expressed at the BBB or in tumours. To date three different categories of 
imaging probes have been described to measure multidrug efflux transporters in 
vivo [117]. 1) Radiolabeled transporter substrates usually developed from drugs 
known to be substrates for Pgp. More recently 2) radiolabeled transporter 
inhibitors as well as 3) radiolabeled prodrugs. 
 Radiolabeled transporter substrates 
 [11C]verapamil  
[11C]verapamil (VPM) is the best validated PET tracer to image Pgp function to 
date. Verapamil, a calcium channel blocker, has been found to be a substrate 
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for Pgp at low concentrations (which are used in PET) but also inhibits the Pgp 
transporter ATP hydrolysis (which initiates substrate extrusion) at high 
concentrations [36]. As it is well characterised both pharmacologically and with 
regards to its metabolic pathways it was thought to be a suitable candidate for a 
PET tracer to quantify Pgp function in vivo non-invasively. In 1996 Elsinga et al. 
[118] were the first to use PET to study multidrug resistance and to measure 
Pgp function. They developed a method using racemic (±) verapamil as a PET 
radiotracer and studied its tissue distribution in vivo in rats and in vitro with 
seizure-free and pharmacoresistant human ovarian carcinoma cell lines [118]. 
The racemic (±) verapamil consists of two enantiomers, the (S) - and (R)- 
verapamil.  In vivo pharmacokinetics and pharmacodynamics of both 
enantiomers in animals and humans are different and the (S)-verapamil is more 
actively metabolised than the R-form, resulting in a 2.5 higher concentration of 
the (R)-enantiomer in plasma [119]. Furthermore (R)-verapamil exerts only 5-
10% of the calcium channel blocking activity of the (S)-enantiomer and (S)-
verapamil is ten times more potent in prolonging PR-intervals in humans [120]. 
As the enantiomers of verapamil have different pharmacokinetics, the 
quantification of racemic (11C)verapamil may be difficult. For this reason 
Luurtsema et al. developed a synthesis of (R)-[11C]verapamil and they found 
that the metabolism was slower than that of the racemic verapamil [121, 122]. 
(R)-[11C]verapamil is a high-affinity substrate of Pgp and is therefore very 
effectively transported by Pgp at the BBB. This results in low brain uptake of this 
radiotracer thus making it difficult to detect regional differences in cerebral Pgp 
function. A possible strategy to overcome the limitation of the low brain uptake of 
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Pgp substrate radiotracer is to perform PET scans after partial blockade by Pgp 
modulating drugs such as cyclosporine A (CsA) or tariquidar (TQD) [70]. The 
third-generation Pgp inhibitor TQD is safer than the non-selective CsA for use in 
human subjects and was shown to lack interaction with metabolism and plasma 
protein binding of (R)-[11C]verapamil [123, 124]. Blocking Pgp with an inhibitor 
allows the radiotracer to enter the BBB and hence increase its uptake and signal 
in the brain.  
Single tissue compartment model to measure Pgp function 
The function of Pgp can be quantified in vivo from dynamic PET data using 
standard compartmental models. Pgp mediates movement of substrates, such 
as verapamil, from brain to plasma. Since we administer the Pgp substrate PET 
tracer ¹¹C-verapamil intravenously, its entry into the brain is limited by P-gp 
activity, and the neteffect is measured as K₁, the transport rate constant from 
plasma to brain; a low net influx from plasma to brain, indicated by a low K₁ 
value, therefore indicates high efflux from the brain and, thus, high Pgp activity. 
As shown in rodent models of Pgp overactivity [125], partial Pgp inhibition 
increases (R)-[¹¹C]verapamil K₁, but this increase is attenuated in areas of high 
P-glycoprotein activity, since a fixed dose of Pgp inhibitor (2 or 3 mg/kg) inhibits 
a lower proportion of binding sites in areas of high P-gp activity than in areas of 
low activity. Therefore partial Pgp inhibition should be used, because if Pgp 
glycoprotein were fully inhibited, brain uptake of ¹¹C-verapamil K₁ would be 
driven by passive diffusion only and differences in Pgp activity could not be 
detected. 
30 
 
Preclinical imaging of Pgp function with [11C]verapamil  
PET analysis with [11C]-verapamil to assess Pgp function at the BBB within the 
intact CNS was first validated using mdr1a knockout mice and showed lower 
[11C]-verapamil uptake in the wildtype mice compared to those in the mdr1a 
knockout mice [126]. In addition it was possible to prove that the reversal of Pgp 
function, i.e. inhibiting Pgp and enabling Pgp substrates to cross the BBB, can 
be monitored by PET. The unselective Pgp inhibitor CsA increased the  [11C]-
verapamil accumulation to levels comparable in mdr1a knockout mice [126]. 
This concept was subsequently replicated in two further studies using the 
racemic [11C]-verapamil and the unselective inhibitor CsA at different doses 
resulting in dose dependent increases of [11C]verapamil by Pgp modulation after 
CsA [127, 128]. Furthermore Bankstahl et al. [124] performed paired (R)-
[11C]verapamil PET scans in a group of 7 healthy Wistar rats before and after 
administration of the new third-generation Pgp inhibitor TQD (15 mg/kg). After 
TQD administration, the distribution volume (DV = the brain-to-plasma ratio) of 
(R)-[11C]verapamil was 12-fold higher than baseline and the influx rate constant 
K1 of (R)-[11C]verapamil into the brain, was about eight-fold higher after TQD 
hereby, demonstrating that (R)-[11C]verapamil PET combined with TQD 
administration is a promising approach to measure Pgp function at the BBB. 
Recently Kuntner et al. used (R)-[11C]verapamil PET in rats before and after the 
administration of different doses of the selective Pgp inhibitors TQD  and 
elacridar [129]. They demonstrated that the median effective dose (the dose 
required to achieve 50% of the desired response in 50% of the population=ED 
50) for TQD is 3.0 +/- 0.2 mg/kg. Furthermore, PET scans after 3 mg/kg TQD 
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resulted in regionally different enhancement of brain activity distribution, with 
lowest distribution volume in cerebellum and highest distribution volume in 
thalamus pointing to regional differences in cerebral Pgp function and 
expression in rat brain. 
Preclinical imaging of Pgp function in pharmacoresistant epilepsy 
with [11C]verapamil 
Following the promising results of (R)-[11C]verapamil in healthy Wistar rats a 
proof of concept study was performed in rats 48 hours after pilocarpine-induced 
status epilepticus (SE). Both control and post-SE rats underwent (R)-
[11C]verapamil PET scans after administration of tariquidar at 3mg/kg [125]. 
Regional PET data was analyzed and Pgp expression was independently 
quantified in the same brain regions using immunohistochemical staining [125]. 
In brain regions with increased Pgp expression (cerebellum, thalamus, 
hippocampus) in SE rats the influx rate constants from blood to brain, K1, of (R)-
[11C]verapamil were significantly decreased relative to control animals, thereby 
supporting the hypothesis of regionally increased cerebral Pgp function in 
epilepsy.  
Clinical Imaging of Pgp function with [11C]verapamil 
Pgp function at the BBB of healthy humans has been imaged and quantified 
using [11C]-verapamil [130]. Recent studies have shown, however, that imaging 
of Pgp function at the BBB in humans may need to take into consideration a 
subject’s age and the genetic polymorphisms of Pgp. Bartels et al. [131] studied 
the Pgp function using [11C]-verapamil PET in 17 healthy volunteers with age 
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18-86. Analysis with statistical parametric mapping showed significantly 
decreased Pgp function in older subjects than in younger subjects in the internal 
capsule and corona radiata white matter and in orbitofrontal regions; thereby 
suggesting that Pgp function declines with increasing age.  Furthermore, 
haplotypes of nucleotide polymorphisms at positions 1236, 2677 snf 3435 of the 
MDR1 gene have been shown to alter Pgp activity in vivo and to alter substrate 
specificity in vitro. However, imaging studies with [11C]-verapamil show that 
pharmacokinetics were unaffected in healthy volunteers who expressed either 
the TTT or the CGC (wild-type) haplotype [132, 133]. 
The promising concept of performing (R)-[11C]verapamil PET scans after 
blockade of Pgp was  recently translated into healthy human subjects [123]. Five 
healthy volunteers underwent paired (R)-[11C]verapamil PET scans before and 
after intravenous administration of tariquidar (2 mg/kg of body weight). TQD 
administration resulted in significant increases in K1, +49% +/- 36% of (R)-
[11C]verapamil across the BBB. The data from this first human study were re-
analyzed region wise using an automated atlas approach to define 43 different 
brain regions as well as parametric maps. No regional differences in TQD-
induced Pgp inhibition were detected, suggesting that there were no regional 
differences in Pgp function in healthy human brain [134]. Shortly after, Eyal and 
co-workers confirmed the results in a study with [11C]-verapamil before and 
during infusion of CsA (2.5 mg x kg(-1) x h(-1)) [135]. Thereby K1 estimates 
were similar across gray-matter regions of the brain and the magnitude of Pgp 
inhibition was comparable across BBB-protected brain structures.   
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Clinical imaging of Pgp function in pharmacoresistant epilepsy with 
[11C]verapamil 
The use of PET to determine Pgp function in epilepsy patients has only started 
recently. A pilot study by Langer et al. [136] used PET and the radiotracer (R)-
[11C]verapamil to test for differences in Pgp activity between epileptogenic and 
non-epileptogenic brain regions of patients with pharmacoresistant unilateral 
mTLE. In this study of five subjects, there was a trend toward asymmetric 
uptake of (R)-[11C]verapamil, favoring the temporal cortex and hippocampus 
ipsilateral to the main seizure focus. Parameter asymmetries were most 
prominent in parahippocampal and ambient gyrus, amygdala, medial anterior 
temporal lobe and lateral anterior temporal lobe. In contrast to temporal lobe 
volumes of interest asymmetries were minimal in regions not involved in 
epileptogenesis located outside the temporal lobe. A caveat of (R)-
[11C]verapamil is that the peripheral metabolism of the radiotracer is significantly 
faster in epilepsy patients compared to healthy controls. This is most likely 
caused by hepatic cytochrome P450 enzyme induction of AEDs [137]. The 
difficulty is that these radiometabolites which are generated from the (R)-
[11C]verapamil are also taken up into the brain tissue independent of Pgp 
function and compromise the quantitative measurement of Pgp function 
especially when comparing different study groups such as patient and healthy 
controls. Additionally, VPM is a high-affinity substrate of Pgp and is therefore 
very effectively transported by Pgp at the BBB. This results in low brain uptake 
of this radiotracer thus making it difficult to elicit and detect regional differences 
in cerebral Pgp function. To overcome this limitation, dynamic PET scans after 
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partial blockade by Pgp modulating drugs such as cyclosporine A (CsA) or 
tariquidar (TQD) can be undertaken [70]. Using in-vivo PET experiments with 
the Pgp-substrate (R)-[11C]verapamil (VPM), we studied 14 pharmacoresistant 
mTLE patients and eight seizure-free mTLE patients due to unilateral 
hippocampal sclerosis (HS) as well as 13 healthy controls, testing the 
hypotheses that Pgp-activity is higher in pharmacoresistant than seizure-free 
mTLE patients and healthy controls, and that Pgp overactivity is most 
pronounced in the epileptic focus [138]. Despite minimising the effect of different 
VPM metabolism between controls and patients by only using the first ten 
minutes of data, we found a significant difference in VPM-K1 globally across all 
analysed brain regions. VPM-K1 values in whole brain were lower in healthy 
controls compared to pharmacoresistant mTLE patients but not different 
compared to seizure-free mTLE patients. Voxel-based SPM analysis showed 
that at baseline, compared to seizure-free patients, pharmacoresistant mTLE 
patients had significantly lower regional VPM-K1, which corresponds to 
increased Pgp activity, in temporal lobe regions. In pharmacoresistant mTLE 
patients, VPM-K1 correlated inversely with average monthly seizure frequency, 
measured at the time of the baseline PET scan (correlation for whole brain: r =-
0.651, p= 0.016; hippocampus: r =-0.604, p=0.029). Because of differences in 
VPM metabolism between mTLE patients and healthy controls we created 
individual VPM-K1 images, which were normalised for global whole brain 
differences in VPM-K1 arisen from this measure being a composite of parent 
VPM and its metabolites. These globally normalized images were then used for 
further analysis to detect regional differences between healthy controls and the 
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two mTLE patient groups. Voxel-based comparison of globally normalised 
images revealed lower VPM-K1 in pharmacoresistant mTLE patients in temporal 
lobe regions compared to healthy controls. Voxel-based SPM analysis before 
and after TQD showed significant differences in increases of VPM-K1 between 
pharmacoresistant mTLE patients and healthy controls with the maximum 
difference in the ipsilateral hippocampus, suggesting that there is regionally 
specific Pgp overactivity for the epileptogenic hippocampus which is functionally 
relevant.  
As it already has been discussed the direct evidence for increased expression of 
Pgp in humans at the BBB is limited to studies from post-mortem and from 
epileptic tissues removed during epilepsy surgery from patients with 
pharmacoresistant epilepsy [8, 10, 106-108], which have substantiated 
assumptions implicit in the transporter hypothesis that Pgp is likely to be the 
most important transporter in pharmacoresistant epilepsy at a structural level. 
However, the functional relevance of this increased expression in humans 
cannot be assessed ex vivo. We therefore compared the results of their VPM-
PET scans with their epileptic tissues removed during epilepsy surgery [138], 
testing the hypotheses that Pgp overactivity demonstrated with VPM-PET 
correlates with Pgp expression established in surgically-resected brain tissue. 
Pgp immunoreactivity was observed in the blood vessels, glia, and neurons in 
the hippocampus and temporal cortex of the five PET-scanned 
pharmacoresistant mTLE patients who underwent surgery. In three 
pharmacoresistant mTLE patients, increases in VPM-K1 after TQD were less 
pronounced, suggesting relatively higher Pgp activity, in the ipsilateral (sclerotic) 
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hippocampus than the ipsilateral temporal neocortex. In accordance with this 
observation, the same three pharmacoresistant mTLE patients also showed a 
higher percentage area of Pgp immunopositive labelling in the sclerotic 
hippocampus compared with the ipsilateral neocortex. Our in-vivo PET 
measurements of Pgp activity correlated with ex-vivo Pgp expression in the 
surgical temporal lobe specimens of those patients who had undergone surgery, 
in keeping with the hypothesis that there is localized Pgp overactivity in 
pharmacoresistant mTLE. This is the first study to date comparing in-vivo Pgp 
activity by using VPM-PET before and after Pgp inhibition with ex-vivo Pgp 
expression from pharmacoresistant mTLE patients who underwent temporal 
lobe resections. In particular, our study is the first study to assess whether this 
Pgp overexpression in pharmacoresistant mTLE is functionally relevant by 
combining in-vivo VPM-PET investigated Pgp activity with ex-vivo analysis of 
Pgp expression in surgically resected tissue. Recently Bauer et al. [139] 
examined seven patients with mTLE in a longitudinal study using VPM-PET 
before and after temporal lobe resections to assess whether postoperative 
changes in seizure frequency and AED load are associated with changes in Pgp 
function and correlated their in-vivo VPM-PET measurements of Pgp function 
with ex -vivo immunohistochemistry from surgical temporal lobe specimens.  
They only performed VPM-PET scans at baseline and did not perform PET 
scans after Pgp inhibition. The seven patients were followed up for a median of 
six years (range 4–7) after epilepsy surgery. They found that pharmacoresistant 
mTLE patients who became seizure-free after surgery had lower VPM-K1 
values, hence increased temporal lobe Pgp activity before surgery, increased 
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Pgp expression in their surgically resected hippocampal specimens, and 
reduced global Pgp activity postoperatively, i.e. higher VPM-K1 values 
postoperatively, compared with patients who continued to have seizures 
postoperatively and had a poorer surgical outcome.  Their results are consistent 
with our findings in seizure-free mTLE patients who have higher VPM-K1 values, 
i.e. reduced Pgp activity, compared to pharmacoresistant mTLE patients. A 
recent post-mortem study showed Pgp overexpression in the sclerotic 
hippocampus of individuals with pharmacoresistant epilepsy, but not in post 
mortem tissue of seizure-free individuals or non-epileptogenic tissue with 
electrode-related injuries [108] indicating that seizures are necessary, but not 
sufficient, for increased Pgp expression. These findings suggest that (i) there is 
measurable, localized Pgp overactivity in pharmacoresistant mTLE which is 
related to seizure activity; (ii) Pgp overexpression is not seen in seizure-
freedom. Pgp overactivity might thus explain why pre-treatment seizure density 
is one factor predicting poor response to AEDs.  
Genetic polymorphism of Pgp might play a role pharmacoresistant mTLE. Only 
two imaging studies have been performed so far to investigate the role of Pgp 
and of its polymorphisms in pharmacoresistant mTLE. In a pilot study with seven 
patients with mTLE no apparent relationship between the ABCB1 genotype and 
the R-[11C]verapamil efflux rate constant k2 could be described but the sample 
size was small [136]. On the other hand a SPECT study in patients with epilepsy 
the 3435CC genotype was associated with reduced brain uptake of 
(99mTc)sestamibi, which was correlated with drug resistance [140]. 
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Furthermore, phenobarbital concentration in the cerebrospinal fluid and 
CSF/serum phenobarbital concentration ratio were significantly lower in patients 
with the CC genotype than in patients with CT or TT genotypes of the ABCB1 
C3435T polymorphism. Additionally, the seizure frequency was also higher in 
CC homozygotes [141].  
 [11C]-N-desmethyl-loperamide 
The radiotracer [11C]-N-desmethyl-loperamide has the advantage that it is 
metabolised to a lesser extent than (R)-[11C]verapamil. It has been used in rats 
[142] as well as monkeys [143] and the first human studies using PET with [11C]-
N-desmethyl-loperamide at baseline [144] and after  Pgp inhibition with TQD 
[145] have been recently carried out. At baseline there is virtually no uptake of 
this radiotracer in the brain. After 2 mg/kg of TQD the brain uptake of 
radioactivity increased only slightly (approximately 30%). In contrast, 4 and 6 
mg/kg of TQD increased brain uptake two- and four-fold, respectively. Until now, 
[11C]-N-desmethyl-loperamide has not been used clinically to study disease in 
patients. On the other hand, [11C]-N-desmethyl-loperamide is a high affinity Pgp 
substrate that virtually shows no brain uptake which makes it unsuitable to map 
regional differences in Pgp function at baseline.  
Radiolabeled Antiepileptic drugs 
It is also possible to label AEDs with a positron emitter. [11C]phenobarbital and 
[11C]phenytoin have been shown to be weak substrates for Pgp and are 
expected to  have higher brain uptake than the high-affinity Pgp  substrate 
[11C]verapamil [79, 146]. They could therefore be better suited to assess 
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regional differences in Pgp function (Mairinger et al., 2011), in particular Pgp 
overexpression. A study in eight patients with pharmacoresistant partial epilepsy 
and two patients without epilepsy showed that [11C]phenytoin concentration 
ratios were lower in the visual cortex in epilepsy patients who had an average 
value of 1.32 (range 1.05-1.66) compared to 1.61 (1.34-1.87) in nonepileptic 
patients [147]. But whether phenytoin concentrations are lower within the 
epileptic focus was not addressed in this study [147]. 
Other radiolabeled Pgp substrates 
Several more radiolabeled drugs and radioligands have been investigated as 
PET tracers for Pgp. The radioligand [18F]MPPF has been developed as an 
alternative to short lived (11C)-labelled tracers for PET studies of  serotonin 5-
HT1A receptors. In microPET studies, treatment with CsA globally increases the 
uptake of [18F]MPPF in rat brain indicating that [18F]MPPF must be a Pgp 
substrate [148]. So far [18F]MPPF has been used in animal studies together with 
the third generation Pgp inhibitor TQD to study Pgp activity [149, 150]. By using 
[18F]MPPF with TQD Bartmann et al. [150] revealed differences in Pgp function 
between pharmacoresistant and seizure-free epileptic rats. TQD pre-treatment 
increased the magnitude of [18F] MPPF K1 in the hippocampus by a mean of 
142% in the non-responders, which significantly exceeded the 92% increase 
observed in the responder group.  The same treatment decreased the mean 
magnitude of [18F] MPPF k2 in the hippocampus by 27% in non-responders, 
without comparable effects in the responder group [150]. Additionally, Bartmann 
et al. [150] demonstrated that the percent reduction of seizure frequency in 
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response to phenobarbital negatively correlated with the impact of tariquidar on 
the hippocampal [18F]MPPF K1 (r = −0.5940; p < 0.05). Moreover, preliminary 
results obtained in a clinical study with ten mTLE patients showed that the Pgp 
inhibitor CsA significantly increased the [18F]MPPF binding potential (the ratio of 
receptor density and radioligand affinity [151]) by 14% in most brain regions, 
regardless of their involvement in seizure generation or propagation [152]. On 
the other hand, a recent study using [18F]MPPF PET in mice and non-human 
primates together with CsA [153] revealed discrepancies in the Pgp-mediated 
transport of [18F]MPPF between mice and non-human primates. Their in vitro 
data indicates that [18F]MPPF is not a substrate of human P-gp and that the 
effect of the Pgp inhibitor CsA on the brain transport of [18F]MPPF in non-human 
primate is related to an increase in the free fraction of tracer in the plasma, 
concluding that it is unlikely that the kinetics of [18F]MPPF brain transport and 
distribution are affected by Pgp activity in humans. In contrast in situ brain 
perfusion showed that Pgp restricted the permeability of the mouse BBB to 3H-
MPPF [153]. 
The PET radioligand [11C]flumazenil which is clinically used for the assessment 
of GABAA receptor mediated inhibition in epilepsy and to localize epileptic foci 
prior to epilepsy surgery has also been suggested to be a Pgp substrate [154, 
155]. [11C]flumazenil was recently used to detect regional differences in Pgp 
functionality in five different brain regions of control and kainate-treated rats, a 
model for TLE, before and after TQD administration.  The study showed that the 
GABAA receptor density (Bmax) was reduced in kainate-treated rats, compared 
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with controls and that there were region-specific Pgp differences, with the 
hippocampus showing the highest Bmax [156]. 
Furthermore, [11C]colchicine [157], [11C]daunorubicin (Elsinga et al., 1996), 
[11C]carvedilol [158], [11C]-GR218231 [159], [18F]paclitaxel [160], various 64Cu-
labeled copper complexes [161], 67Ga/68Ga radiopharmaceuticals [162], 
[11C]TMSX, [11C]MPDX, 11C]donepezil [154], [11C]carazolol and 
[18F]fluorocarazolol [163] have been used to study Pgp. However, only limited in 
vivo data have been reported so far and it is not yet clear if these radiotracers 
are useful for PET studies to image Pgp function in human. 
Radiolabeled transporter inhibitors 
Another complementary approach to assess the Pgp system with PET is the use 
of radiotracers which bind to Pgp without being transported. Such radiotracers 
would asses the transporter distribution and give a signal increase rather than a 
decrease (as will Pgp substrates) in brain regions that overexpress Pgp 
(Löscher and Langer, 2010). Several PET radiotracers based on the Pgp 
inhibitors have been reported to date: [11C]laniquidar, [11C]MC-18, [11C]quinidine 
[11C]elacridar and [11C]tariquidar [134, 164-166]. These new radiotracers have 
so far only been tested in animal models of naïve, transporter knock-out and 
epileptic rodents with rather surprising results. The cerebral uptake was lower 
than expected at baseline and increased several-fold rather than decreased 
after administration of unlabelled inhibitors [134, 164, 165]. These radioligands 
were administered at very low (tracer) concentrations and could behave 
differently than at high concentrations. It is hypothesized that the low brain 
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uptake, i.e. the rather substrate-like behaviour of these radiotracers, could be 
caused by other multidrug efflux transporters (such as BCRP) at the BBB 
transporting the radiotracers out of the brain [117].  
NEUROIMAGING OF PGP WITH SPECT 
[99mTc]sestamibi was originally developed as a K+ analog for imaging 
myocardial ischemia. It has been shown to be a substrate for Pgp [167]. In 
humans, [99mTC]sestamibi was reported to image Pgp efflux transport in 
multidrug resistant  cancers (Luker et al., 1997). However, it was found not to be 
an ideal substrate radioligand as it is not a selective substrate for Pgp  but also 
for other multidrug efflux transporters (such as MRP1) (Hendrikse et al., 1998). 
Furthermore in contrast to PET, SPECT does not enable quantitative 
measurements of uptake and efflux kinetics of Pgp substrates and thus has only 
limited use in studying Pgp function in the BBB (Löscher and Langer, 2010). 
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DISCUSSION AND FUTURE WORK 
Over the recent years molecular imaging techniques have helped to investigate 
mechanisms of pharmacoresistance in epilepsy. In particular PET has been 
used to evaluate the transporter hypothesis and demonstrated that Pgp is 
increased in pharmacoresistant epilepsy. Several open questions remain and 
molecular imaging techniques can help to enhance our understanding of 
underlying mechanisms for pharmacoresistance in epilepsy. 
Using non-ivasive imaging with PET enables us to identify individual patients 
where pharmacoresistance is caused by Pgp overactivity and potentially 
individualise treatment. Moreover, comparative studies between 
pharmacoresistant and seizure-free epilepsy patients can enable testing for a 
correlation between Pgp function and the pharmacoresponse. This imaging 
technique can also guide patient selection for future clinical studies. In particular, 
PET imaging of Pgp function may allow individualized application of approaches 
to overcome Pgp–associated pharmacoresistance. In the future combined 
imaging and clinical trials of novel treatment strategies, such as Pgp inhibitors or 
modulators of overexpression in patients who have Pgp overactivity on VPM-
PET could be employed. Targeting Pgp by modulators can enhance the efficacy 
of antiepileptic drugs. The compound verapamil is a substrate for Pgp at low 
concentrations (which is used in PET), but, like many substrates, verapamil is 
also an inhibitor for Pgp at high concentrations [130]. Verapamil was among the 
first identified inhibitors of Pgp and it may function to block Pgp–modulated 
efflux of AEDs in the brain, thereby raising the intracellular concentration of 
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AEDs [168]. The third-generation modulator TQD increased the efficacy of 
phenytoin in a chronic rat epilepsy model and helped to overcome 
pharmacoresistance to phenobarbital in chronic rat epilepsy models [169]. On 
the other hand, first- and second-generation inhibitors are not specific for Pgp 
alone and can exert additional pharmacodynamic and pharmacokinetic effects. 
Third-generation inhibitors are considered fairly specific.  But there is recent 
evidence for the third-generation inhibitor TQD that it can also affect the efflux 
transporter BCRP/ABCG2. Moreover, long-term inhibition of this transporter 
needs to take into account that Pgp serves as a protective mechanism and 
gatekeeper in several blood tissue barriers as well as hematopoietic cells [170]. 
In addition to limiting access of harmful xenobiotics to sensitive tissues or cells, 
Pgp also accelerates extrusion of xenobiotics based on its efflux function in the 
liver and kidneys. Therefore, alternate approaches that leave basal transporter 
expression and function unaffected might offer advantages for tolerability and 
safety issues. Preventing seizure-associated transporter upregulation might offer 
an intriguing alternate approach to overcoming transporter associated 
pharmacoresistance [69, 171].  
Of course, the ideal PET or SPECT radiotracer for studies in epilepsy patients 
would be a radiolabelled AED and could represent an alternative strategy for 
directly probing the clinical relevance in patients showing resistance to individual 
AEDs. Additionally, as postulated in the transporter hypothesis, the 
overexpression of efflux transporters restricts the entry of AEDs into the brain; 
thus AED concentrations in the affected areas should be lower. Even though 
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microdialysis for measurement of local brain AED concentrations in human 
epileptic brain tissue is feasible, ethical and methodological issues limit the use 
beyond experimental protocols [172] and not many data are available. PET 
experiments with a Pgp inhibitor and radiolabelled AEDs have not been done, 
but will important for direct assessment of brain concentration levels of AEDs in 
humans. 
PET is non-invasive and can study the contribution of efflux transporters in 
pharmacoresistant epilepsy in vivo. Thereby it can be applied to various different 
epilepsy syndromes. The mechanisms underlying pharmacoresistance have so 
far mainly been addressed in focal epilepsies, primarily in TLE [3, 8]. This is 
partly because temporal lobectomy is the commonest epilepsy surgical 
procedure performed and hippocampal or mesial sclerosis is the commonest 
pathologic finding in pharmacoresistant epilepsy [173]. It is therefore not 
surprising that temporal lobe pathologies, in particular hippocampal sclerosis, 
are the most studied epileptogenic lesions for the upregulation of multidrug 
efflux transporters [3]. It remains to be determined whether overexpressed 
multidrug efflux transporters are underlying mechanism of pharmacoresistance 
exclusive in focal epilepsies or also present in other epilepsy syndromes, such 
as generalised epilepsy.  
PET has the benefit to study the whole brain and hereby regional differences in 
pharmaoresistant epilepsy can be investigated beyond the seizure focus. It is 
currently unclear whether epilepsy, uncontrolled seizures or chronic treatment 
with AEDs stimulate a global rather than regional response of Pgp function. 
46 
 
Increased expression of Pgp in the region of the epileptic focus was found in 
patients with pharmacoesistant epilepsy [3]. However studies investigating Pgp 
overexpressions in human brain tissue have mainly been derived from “epileptic” 
brain tissues removed during epilepsy surgery and there is a lack of control 
regions from the same subject as well as “normal” controls for comparison [3]. In 
rat models of TLE the Pgp overexpression was restricted to the hippocampus 
and parahippocampal regions [67].  On the other hand in a recent PET study 
assessing Pgp function in a rat model of TLE there was an increase of Pgp in 
regions beyond the epileptogenic focus in the thalamus and cerebellum [125]. 
Thus in addition to examining regional differences, PET is also able to assess 
whether there are discrepancies in the expression and function of multidrug 
efflux transporters in pharmacoesistant epilepsy. 
PET can also be used to compare the expression and function of multidrug 
efflux transporters in different groups of AED responders such as 
pharmacoresistant, seizure-free and remitting-relapsing epilepsy patients. PET 
data in humans investigating Pgp overexpression in patients with seizure-free or 
remitting-relapsing epilepsy are lacking. Experimental data indicates that AED 
responders and non-responders differ in the extend of Pgp upregulation [69]. 
Additionally, neurobiological mechanisms of pharmacoresistance may be 
different in patients who have never responded to AEDs versus those who 
progressed to drug-resistance after they responded initially to therapy. 
Furthermore, the mechanisms of reversing pharmacoresistance may differ from 
those generating pharmacoresistance.   
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As PET is non-invasive thus several scans can be given to the same patient 
over the course of the disease. Therefore, the progression from naïve to acute 
and then to chronic seizures can truly be studied. Not only could the effect of 
seizures which causes an upregulation of Pgp [45, 101] be investigated but also 
the inherent severity model of epilepsy could be studied this way. PET allows 
the investigators to examine the living brain before the disease is induced and 
over the time course of symptoms and even therapies.  
Perhaps more importantly, new treatments can be evaluated in 
pharmacoresistant patients over time. The transporter hypothesis has gained 
interest in recent years, because it opens the possibility to discover potential 
therapeutical targets for drug resistance by either inhibiting or bypassing Pgp or 
other involved efflux transporters [70]. In this regards Lazarowski et al. recently 
suggested using add-on therapy by co-administering Pgp inhibitors, to overcome 
drug resistance and contribute to the effectiveness of AED treatment [174] . For 
example calcium channel blockers such as verapamil or nimodipine are 
substrates for Pgp but also competitively inhibit the efflux of other Pgp 
substrates such as AEDs. In paediatric refractory epilepsy cases with persistent 
sub therapeutic AED blood levels, nimodipine administration together with AEDs 
resulted in improvement of medical condition and blood levels of AEDs [174, 
175]. Similarly Ianetti et al. [176] described an 11-year old boy with status 
epilepticus which was unresponsive to treatment. On day 37 of continues SE 
treatment with verapamil was started. 1.5 hour after initiation of the verapamil 
infusion, the patient regained consciousness was able to breathe spontaneously 
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and the electrical SE promptly disappeared. Ultimately, PET could serve as a 
predictive tool for detection of Pgp mediated drug-resistance in epilepsy. By 
identifying patients with increased Pgp alternate therapeutic approaches or 
novel AEDs as well as straightforward decisions regarding non pharmacological 
treatment strategies, including epilepsy surgery.  
The next step in the future will be to combine imaging and clinical trials of novel 
treatment strategies, with Pgp inhibitors or modulators in patients who have Pgp 
overactivity on VPM-PET aimed at reversing drug resistance with selection of 
optimal patients and assessment of molecular targets. But further development 
of the approach needs to also consider tolerability issues specific to the different 
targets [69]. In particular more evaluation is needed in view of the controversial 
findings which AEDs are Pgp substrates and, thus, determine the penetration of 
which particular AEDs are affected by Pgp. Of course, evidence that some 
antiepileptic drugs are affected by the human Pgp isoform and that others are 
not substrates, needs to be considered when drawing conclusions about the 
future promises of any approach to modulate Pgp expression or function. 
Modulating Pgp might, therefore, only help to overcome resistance to selected 
antiepileptic drugs, but might not help to overcome multidrug resistance. More 
precise knowledge about substrate specificities is, therefore, crucial to guide the 
putative future application of respective diagnostics as well as therapeutic 
strategies to selected patients.  
Finally, although recent studies provided the proof of concept for the transporter 
hypothesis and show that there is functionally relevant Pgp overactivity in 
49 
 
pharmacoresistant mTLE [138], the critical question remains whether it sufficient 
to overcome Pgp overexpression as one putative mechanism of a multifactorial 
problem or that other mechanisms such as intrinsic disease severity, alterations 
in targets, different gene variants or network alterations need to be taken into 
account and in the future further investigated. Given the complexity of epilepsy, 
it is unlikely that pharmacoresistant epilepsy is caused by a single mechanism 
but instead is due to several mechanisms which may even occur in the same 
patient. Overcoming pharmacoresistance in epilepsy represents a challenge and 
will necessitate a multifactorial approach and the combined efforts of basic and 
clinical epilepsy researchers [177]. 
CONCLUSION 
Pharmacoresistance in epilepsy is a complex problem and several mechanisms 
are likely to contribute to therapeutic failure. Molecular imaging techniques in 
particular PET has provided evidence for the transporter hypothesis of 
overexpression of multidrug efflux transporters in pharmacoresistant epilepsy. 
Molecular imaging methods can help to further investigate mechanisms 
underlying pharmacoresistance in epilepsy. 
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